1. Home
  2. SBET vs CGEM Comparison

SBET vs CGEM Comparison

Compare SBET & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SharpLink Gaming Ltd.

SBET

SharpLink Gaming Ltd.

SELL

Current Price

$5.18

Market Cap

1.2B

Sector

Technology

ML Signal

SELL

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$8.67

Market Cap

999.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBET
CGEM
Founded
1995
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
999.4M
IPO Year
2025
2020

Fundamental Metrics

Financial Performance
Metric
SBET
CGEM
Price
$5.18
$8.67
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
12
Target Price
$16.13
★ $34.70
AVG Volume (30 Days)
★ 9.4M
778.3K
Earning Date
11-06-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ $28,055,000.00
N/A
Revenue This Year
$81.28
N/A
Revenue Next Year
$47.36
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 666.04
N/A
52 Week Low
$4.46
$8.23
52 Week High
$12.29
$23.19

Technical Indicators

Market Signals
Indicator
SBET
CGEM
Relative Strength Index (RSI) 27.32 26.07
Support Level $5.06 N/A
Resistance Level $5.90 $16.31
Average True Range (ATR) 0.38 1.25
MACD -0.10 -0.34
Stochastic Oscillator 4.79 2.30

Price Performance

Historical Comparison
SBET
CGEM

About SBET SharpLink Gaming Ltd.

Sharplink Inc is one of those publicly traded companies to adopt ETH as its primary treasury reserve asset. This move reflects the Company's commitment to align corporate treasury with the future of programmable finance, digital capital markets, and decentralized infrastructure. The Company also operates an online affiliate marketing company that delivers different fan activation solutions to its sportsbook and online casino gaming partners. The company operates in two reportable segments: ETH Treasury Management and Affiliate Marketing. The majority of its revenue is generated from the ETH Treasury Management. Geographically, the company operates in the United States and the rest of the world.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: